Tamtam Try Tamtam free
Bruker logo

Bruker account plan

advanced analytical instrumentation solutions

At a glance

Bruker makes scientific instruments and diagnostics (NMR, mass spectrometry, X-ray, microscopy): $3,436.5 million FY2025 revenue, about 11,085 staff.

Bruker, headquartered in Billerica, Massachusetts, develops, manufactures and distributes scientific instruments and analytical and diagnostic solutions across magnetic resonance, mass spectrometry, chromatography, X-ray, microscopy, metrology and molecular spectroscopy. Its customers are academic and government research facilities, pharma and biotech companies, hospitals and clinical microbiology labs, semiconductor and industrial companies, and defense and security agencies, served by direct sales forces in North America, Europe, China, Japan and Asia Pacific plus distributors. FY2025 revenue was $3,436.5 million (+2.1%, organic -3.7%), with GAAP operating income of $68.2 million and a non-GAAP operating margin of 12.6%. It had approximately 11,085 employees at December 31, 2025, about 20.2% in the United States. Frank H. Laukien is Chairman, President and CEO, and Laukien family members owned about 32% of common stock at the end of 2025.

Business units

Strategic priorities

Cost-out programme
A cost savings initiative announced in August 2025 targeted $100 million to $120 million of annualized savings by the end of 2026; the CFO said in Q3 2026 Bruker is on track for a $140 million annualized run rate. The new group structure is expected to add $20 million of cost reductions in fiscal year 2027.
Margin recovery
Management aims to drive back towards a 20% EBIT operating margin, then the low 20s, and expects more than 100 basis points of further operating margin expansion in 2027 with double-digit EPS growth.
Simpler segment structure
Effective July 1, 2026 Bruker reorganised into four groups (Biosystems, Nano, BMID and BEST) to streamline decision making, accountability and customer focus.
Semiconductor metrology and deep tech
Semiconductor metrology bookings grew more than 30% year to date in 2026 on demand for high bandwidth memory and advanced packaging; the deep tech portfolio is about 15% of the business and semi metrology has about a 30% EBIT margin.
Post-genomic research and diagnostics
New timsTOF and timsOmni proteomics workflows, the Mimetas organ-on-a-chip platform and molecular diagnostics growth, which the CEO calls a high single-digit growth area long term.

Latest results

In Q3 2026 revenue was $874.0 million, up 1.6% from $860.5 million, with organic growth of 0.7%. Non-GAAP operating margin rose to 16.3% from 12.3% and non-GAAP EPS rose 24.4% to $0.56, while the GAAP operating loss of $91.0 million reflected $174.5 million of goodwill impairment. Nine-month revenue was $2,535.9 million (+3.1%, organic -0.3%). BSI book-to-bill exceeded one for the fifth consecutive quarter, and U.S. academic bookings grew for the first time since the 2025 NIH funding disruption. FY2026 guidance is revenue of $3.52 to $3.56 billion and non-GAAP EPS of $2.10 to $2.15.

Investments and deals

Tofwerk and Mimetas
Bruker acquired the remaining 60.0% of Tofwerk on January 6, 2026 ($74.0 million net of cash) and a majority of Mimetas B.V. on August 7, 2026 ($60.7 million).
Atinary Technologies
A strategic collaboration and minority investment integrating Chemspeed lab automation and Bruker instruments into agentic AI chemistry workflows.
Earlier platform acquisitions
2024 acquisitions totalled $1,599.6 million, including ELITechGroup and NanoString; 2025 acquisitions fell to $103.3 million as the focus moved to integration.
Balance sheet repair
In September 2025 Bruker issued $690 million of 6.375% Mandatory Convertible Preferred Stock to repay term loans and revolver borrowings; total debt was $1.7 billion at September 30, 2026 and net leverage 2.4x.

Challenges and risks

Tariffs
U.S. tariffs on imports from Germany and Switzerland reduced bookings, revenue and margins in 2025; refunds were filed after the February 20, 2026 Supreme Court ruling, but other tariff programmes remain.
U.S. academic funding
Reduced and delayed NIH, NSF and DOE funding had a material adverse effect; U.S. academic revenue was down more than $15 million year on year in Q2 2026.
Goodwill impairments
Spatial biology and cellular analysis took $211.0 million of goodwill impairment in 2026 and Chemspeed $98.4 million, after operating results below expectations.
Weak industrial, biopharma and Asia demand
Slower industrial and semiconductor demand drove the FY2025 organic decline, and nine-month 2026 Asia Pacific revenue fell to $673.7 million from $727.2 million.

What leadership says

“we expect revenue growth acceleration, continued margin expansion and double-digit EPS growth in FY27.”

Frank H. Laukien, Chairman, President and CEO · Bruker Q3 2026 results press release, November 4, 2026

“We are on track to achieve our $140 million annualized run rate cost-out target.”

Gerald N. Herman, EVP and CFO · Bruker Q3 2026 earnings call, November 4, 2026

“our goal is to drive back towards a 20% EBIT operating margin as quickly as possible and then more gradually move up to the low 20s in EBIT and mid-20s in EBITDA”

Frank H. Laukien, Chairman, President and CEO · Bruker Q2 2026 earnings call, August 2026

Where a supplier can help

Cost-out and procurement savings
The annualized cost-out target touches supply chain, manufacturing, commercial operations, administration and R&D, so suppliers that lower cost in those functions fit the programme.
Integration of acquired businesses
Tofwerk, Mimetas and the earlier ELITechGroup and NanoString deals, plus the July 2026 regrouping, create integration work in systems, data and processes.
Semiconductor metrology capacity
Semi metrology orders with 9 to 24 month lead times convert mostly in fiscal 2027 and 2028, which calls for manufacturing, components and logistics support for that business.
Tariff and supply chain resilience
Tariffs on German and Swiss imports and limited-source components are stated risks; trade compliance and alternative sourcing services address them.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Bruker?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Bruker

What does Bruker do?

Bruker develops, manufactures and distributes scientific instruments and analytical and diagnostic solutions, including NMR, mass spectrometry, X-ray, microscopy and semiconductor metrology, for research, pharma, clinical and industrial customers.

What is Bruker's revenue?

FY2025 revenue was $3,436.5 million, up 2.1%. For FY2026 Bruker guides revenue of $3.52 to $3.56 billion.

How many employees does Bruker have?

Approximately 11,085 employees at December 31, 2025, about 20.2% of them in the United States.

Who leads Bruker?

Frank H. Laukien is Chairman, President and CEO, and Gerald N. Herman is Executive Vice President and CFO.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)